Literature DB >> 8148213

Examination of some factors responsible for a food-induced increase in absorption of atovaquone.

P E Rolan1, A J Mercer, B C Weatherley, T Holdich, H Meire, R W Peck, G Ridout, J Posner.   

Abstract

1. Atovaquone is a potent antiprotozoal slowly and irregularly absorbed after administration as tablets to fasting volunteers. A series of studies was performed to investigate the effects of food, bile and formulation on atovaquone absorption. 2. In 18 healthy male volunteers, a high-fat breakfast administered 45 min before 500 mg atovaquone as tablets increased AUC by 3.3-fold (95% CI 2.8-4.0) and Cmax 5.3-fold (4.3-6.6) compared with fasting. 3. The absorption of atovaquone from tablets was examined in 12 healthy male volunteers after an overnight fast, following toast alone, toast with 28 g butter (LOFAT), or toast with 56 g butter (HIFAT). Compared with absorption when fasted, toast had no significant effect but LOFAT increased AUC 3.0-fold (2.1-4.2) and Cmax 3.9-fold (2.6-5.8). HIFAT increased AUC 3.9-fold (2.7-5.5) and Cmax 5.6-fold (3.8-8.4). 4. The absorption of atovaquone was examined in nine healthy fasting male volunteers from tablets, an aqueous suspension, and an oily solution/suspension in miglyol (fractionated coconut oil). Compared with tablets, AUC following the aqueous suspension was increased 1.7-fold (1.0-2.7) and Cmax 2.4-fold (1.7-3.5). Following miglyol, AUC was increased to the same extent but Cmax was only increased 1.8-fold (1.2-2.6). 5. Atovaquone absorption was examined in eight healthy fasting male volunteers following an i.v. infusion of cholecystokinin octapeptide (CCK-OP) which decreased gallbladder volume by 82% (73%-90%) on occasion 1 or saline on occasion 2. AUC(0,12) was increased following CCK-OP by 1.6-fold (1.1-2.4) and Cmax by 1.5-fold (0.98-2.4).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8148213      PMCID: PMC1364703          DOI: 10.1111/j.1365-2125.1994.tb04232.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans.

Authors:  T R Bates; J A Sequeria
Journal:  J Pharm Sci       Date:  1975-05       Impact factor: 3.534

2.  THE FUNCTION OF BILE SALTS IN FAT ABSORPTION. THE SOLVENT PROPERTIES OF DILUTE MICELLAR SOLUTIONS OF CONJUGATED BILE SALTS.

Authors:  A F HOFMANN
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

3.  Biovailability of phenytoin in lipid containing dosage forms in rats.

Authors:  S Chakrabarti; F M Belpaire
Journal:  J Pharm Pharmacol       Date:  1978-05       Impact factor: 3.765

4.  Intraluminal bile-salt deficiency in the pathogenesis of steatorrhoea.

Authors:  B W Badley; G M Murphy; I A Bouchier
Journal:  Lancet       Date:  1969-08-23       Impact factor: 79.321

5.  Parameters affecting absorption of griseofulvin in a human subject using urinary metabolite excretion data.

Authors:  P Kabasakalian; M Katz; B Rosenkrantz; E Townley
Journal:  J Pharm Sci       Date:  1970-05       Impact factor: 3.534

6.  The effect of oils on the lymphatic absorption of DDT.

Authors:  K J Palin; C G Wilson; S S Davis; A J Phillips
Journal:  J Pharm Pharmacol       Date:  1982-11       Impact factor: 3.765

7.  Drug absorption in patients with T-tube after cholecystectomy.

Authors:  S Aukee; V M Venho; J Jussila; P Karjalainen
Journal:  Ann Clin Res       Date:  1975-02

8.  Influence of gallstones and ursodeoxycholic acid therapy on gallbladder emptying.

Authors:  I C Forgacs; M N Maisey; G M Murphy; R H Dowling
Journal:  Gastroenterology       Date:  1984-08       Impact factor: 22.682

9.  Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro.

Authors:  D J Hammond; J R Burchell; M Pudney
Journal:  Mol Biochem Parasitol       Date:  1985-01       Impact factor: 1.759

10.  Real-time ultrasound. A new method for studying gall-bladder kinetics.

Authors:  A Palframan; H B Meire
Journal:  Br J Radiol       Date:  1979-10       Impact factor: 3.039

View more
  31 in total

1.  Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data.

Authors:  E Nicolaides; E Galia; C Efthymiopoulos; J B Dressman; C Reppas
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

2.  Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration.

Authors:  E Nicolaides; M Symillides; J B Dressman; C Reppas
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

Review 3.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 5.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.

Authors:  M D Edstein; B M Kotecka; K L Anderson; D J Pombo; D E Kyle; K H Rieckmann; M F Good
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 7.  Piperaquine: a resurgent antimalarial drug.

Authors:  Timothy M E Davis; Te-Yu Hung; Ing-Kye Sim; Harin A Karunajeewa; Kenneth F Ilett
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?

Authors:  Bui Tri Cuong; Vu Quoc Binh; Bui Dai; Dinh Ngoc Duy; Claire M Lovell; Karl H Rieckmann; Michael D Edstein
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

9.  Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients.

Authors:  R Dixon; A L Pozniak; H M Watt; P Rolan; J Posner
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?

Authors:  Sibylle Winterhalter; Katja Severing; Johannes Stammen; Anna Karina Maier; Erhard Godehardt; Antonia Maria Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-02       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.